Intraocular inflammation as the main manifestation of *Rickettsia conorii* infection

Archimedes LD Agahan1,3
Jenice Torres1
Graciana Fuentes-Páez1
Hernan Martínez-Osorio1
Antonio Orduña2
Margarita Calonge1
1Ocular Immunology and Uveitis Unit, Institute of Applied Ophthalmobiology (IOBA), 2Microbiology Department, University of Valladolid, Valladolid, Spain; 3Department of Ophthalmology and Visual Sciences, University of the Philippines, Philippine General Hospital, Manila, Philippines

Objective: To report the clinical features and management of seven cases of intraocular inflammation caused by *Rickettsia* infection and review published literature.

Methods: *Rickettsia conorii* or *Rickettsia* spp. infection was diagnosed based on the following criteria: (1) positive serology according to the European Guidelines, (2) titer normalization after specific treatment, and (3) complete resolution of ophthalmic disease and accompanying symptoms after antibiotic therapy.

Results: Seven patients were referred for uveitis of unknown etiology. All came from regions where Mediterranean spotted fever is prevalent. One patient met the European guidelines criteria for *Rickettsia* spp. infection, while the other six cases met the criteria for *R. conorii* infection. The main symptoms were visual loss, floaters, eye redness, photophobia, and ocular pain. Predominant ophthalmic signs included vasculitis, choroiditis, vitritis, and macular edema. All patients required antibiotic treatment that resulted in the remission of the infection. Doxycycline was the first choice and the only antibiotic used to treat four patients. One patient needed ciprofloxacin as a second antibiotic after not responding to doxycycline. Two patients had doxycycline as a second antibiotic after not responding primarily to sulfonamides (which had been given after 2–3 days of doxycycline gastric intolerance); one of these patients needed ciprofloxacin as a third antibiotic.

Conclusion: Intraocular inflammation can occur as the main manifestation of *Rickettsia conorii* or *Rickettsia* spp. infection. It should be considered as a differential diagnosis for uveitis especially for patients living in countries where this infection is endemic in the world. Antibiotic treatment remains effective in the management of *Rickettsia* infection.

Keywords: intraocular inflammation, Mediterranean spotted fever, *Rickettsia conorii*, uveitis

Introduction

Mediterranean spotted fever (MSF) or boutonneuse fever is an acute systemic disease, first described in 1910 in Tunisia by Conor and Bruch.1 It is transmitted to humans by tick bites. The etiologic agent is *Rickettsia conorii*, a small coccobacillary intracellular bacterium belonging to the spotted fever group of the *Rickettsia* family.2 MSF is an endemic disease occurring during spring and summer in Asia, Africa, and Mediterranean countries.3 The pathophysiology of *R. conorii* infection is characterized by vascular invasion causing injury and tissue necrosis.4 Endothelial cells are the organism’s main target.4

In addition to general malaise, the clinical symptoms of *Rickettsia* infection include the triad of fever, skin rash, and headaches. There are many reports on the systemic manifestations of MSF, but reports on the ophthalmic presentations of this disease
are scarce. The existing reports are short communications or correspondence and describe ocular manifestations that include conjunctivitis, keratitis, anterior uveitis, panuveitis, retinitis, retinal vascular occlusions, retinal vasculitis, intraretinal hemorrhages, macular edema, macular star, optic disc edema, optic neuritis, and multiple evanescent white dot syndrome-like lesions.1,2,3-22

Guidelines for the diagnosis of tick-borne bacterial diseases in Europe have been reported, and consequently serologic antibody titers for the diagnosis of *R. conorii* and other *Rickettsia* spp. infections have been standardized.21 We describe the largest reported series to date of *R. conorii* and *Rickettsia* spp. infection with uveitis as the predominant manifestation.

**Materials and methods**

Seven patients diagnosed with uveitis due to *Rickettsia* infection and cared for at the Ocular Immunology and Uveitis Unit of IOBA, University of Valladolid, Spain, between May 1999 and March 2006, were identified from a database. We performed the retrospective portion of this study by reviewing clinical histories. Beginning in March 2005, patients were prospectively followed. The Ethics Committee of the University of Valladolid approved this study. Each patient completed a detailed uveitis questionnaire at the initial visit. Comprehensive family, personal, and ophthalmic histories were obtained. A complete ocular examination was performed at every visit, including best-corrected visual acuity, slit-lamp examination, tonometry, and ophthalmoscopy. Fluorescein angiography or other tests were performed when considered necessary. Uveitis was classified as anterior, intermediate, posterior, or panuveitis.24 Demographic data were recorded to include age, race, gender, city of origin, systemic signs and symptoms, previous treatments, serologies, and treatment initiated at our institution. We also recorded the delay to diagnosis as the elapsed time between initial symptoms and our diagnosis and the follow-up time as the elapsed period between diagnosis of rickettsiosis and last visit. Additionally, the average time to achieve therapeutic success was recorded as the elapsed time between last antibiotic treatment and the last visit. Clinical findings and follow-up results were recorded. Ocular symptoms and signs were recorded by eye.

According to the guidelines for the diagnosis of tick-borne bacterial diseases in Europe,23 diagnostic criteria for *R. conorii* infection in suspected cases of MSF are IgG titers ≥128 and/or IgM titers ≥64 as determined by serum immunofluorescence. IgG titers ≥64 and/or IgM titers ≥32 are considered indicative of infection by other *R. spp.*23 We considered that to diagnose a uveitis case as caused by *Rickettsia*, the three following criteria had to be met: (1) positive serology by ELISA testing according to the European guidelines as stated above, (2) normalization of antibody titers 3 months after specific antibiotic treatment, and (3) complete resolution of ophthalmic disease and accompanying symptoms. This last criterion means that diagnosed patients had to be cured (absence of symptoms, no inflammatory cells, and disappearance of all active signs of inflammation) with no further recurrence. The patient was considered “cured” when titers became negative and inflammation disappeared and did not recur.

**Results**

Demographic and extracocular findings are reported in Table 1, whereas variables concerning ophthalmic involvement are shown in Table 2. A total of ten eyes of seven Caucasian subjects, four males and three females, 39.1 ± 16.0 years old (mean ± SD; range: 8–54; median: 43 years) were included in this study. The mean follow-up time was 46.4 ± 26.9 months (range: 12–84 months; median: 40 months). The mean follow-up of elapsed time between the last successful antibiotic treatment and last visit was 35.2 ± 29.6 months (range: 6–72 months; median: 20 months). Six patients came from Extremadura in the southwest region of Spain and one from Andalucia in the southernmost region.

The main symptoms included loss of vision in seven eyes and floaters in four eyes. Less frequently, the patients presented with redness, photophobia, and pain. Ophthalmic examinations revealed vitritis in nine eyes, macular edema in five eyes, and vasculitis, the predominant feature as expected, in six eyes. The vasculitis was venous and focal in nature with sheathing and mild leakage in all cases, except in Case 5, where phlebitis was more diffuse. Other ophthalmic signs included central retinal vein thrombosis in Case 5 (Figure 1A and 1B), due to venous inflammation, focal choroiditis, multifocal choroiditis, focal keratopathy, anterior chamber cells, posterior synechiae, retinal hemorrhages, and papillitis. Four cases were unilateral and three were bilateral. All patients had frequent contact with dogs and two patients were aware of insect bites, including one by tick and one by flea. One of the two patients recalled a cutaneous lesion compatible with erythema migrans after a tick bite. Three patients described transient extracocular manifestations of arthralgias and fever that had already disappeared before their first visit with us.

Our choice of antibiotic treatment followed the guidelines proposed by Raoult et al.23 One antibiotic course of treatment (doxycycline 100 mg/12 hours for 8–10 weeks) was sufficient in four patients (Cases 1, 2, 3, and 5). Two courses were
species, can be classified into three groups: (1) rickettsiosis due
to bacteria of the genus Rickettsia; (2) spotted fever
group (SFG) and the typhus group Rickettsiae; R. rickettsii
is responsible for rocky mountain spotted fever (RMSF),
R. conorii for MSF; (2) ehrlichioses and anaplasmoses, due
to bacteria within the family Anaplasmataceae; and (3) scrub
typhus, due to Orientia tsutsugamushi.23

Rickettsioses from the SFG, perhaps the best known,
are characterized by development of tache noir at the site
of the arthropod bite, high fever, myalgia, headaches, and
occasional gastrointestinal and neurological signs. RMSF
is an important human rickettsiosis in the United States,
but other rickettsial spotted fevers are encountered mostly
in other continents.26,27 For RMSF, the systemic disease
can be accompanied by bilateral optic disk edema, cotton-
wool spots, and tortuous retinal veins.28 In other cases with
no systemic manifestations, RMSF can present as keratic
precipitates, anterior chamber and vitreous cells, optic disc
edema, retinal hemorrhages, retinal arteriolar sheathing,
and macular star.29

The dog tick Rhipicephalus sanguineus, which inoculates
R. conorii into the skin while feeding, transmits MSF. Patients
present with a characteristic tache noir in 50%–75% of
cases and systemic disease one week after contact. They
have a good prognosis.26 The pathophysiologic hallmark is
vascular endothelial cell invasion by the organism, causing
endothelial injury and tissue necrosis. It is an endemic disease
in Mediterranean countries, including Spain, with reported
cases in the regions of Extremadura, Andalucia, Castilla y
León, and the east coast.30–32 R. conorii, R. mongolotimonae,
### Table 2 Description of ocular pathology and results at end of follow-up

<table>
<thead>
<tr>
<th>Case</th>
<th>Eye</th>
<th>Initial (referral) diagnosis</th>
<th>Ocular symptoms</th>
<th>Type of uveitis*</th>
<th>Pathologic ocular signs at first visit**</th>
<th>Pathologic ocular signs at end of FU/ (time to reach clinical remission after antibiotic treatment)*</th>
<th>BCVA at end of FU/reason for visual loss</th>
<th>Worst BCVA on FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>OS</td>
<td>Uveitis due to toxoplasmosis</td>
<td>Loss of vision Floaters</td>
<td>Posterior</td>
<td>+1 Vitritis&lt;br&gt;Vasculitis&lt;br&gt;Choroiditis&lt;br&gt;Retinal hemorrhages</td>
<td>Peripheral retinal vessel attenuation&lt;br&gt;Foveal ischemia (12 weeks)</td>
<td>0.100&lt;br&gt;Foveal ischemia</td>
<td>0.100</td>
</tr>
<tr>
<td>2</td>
<td>OD</td>
<td>Idiopathic panuveitis</td>
<td>Loss of vision Redness Photophobia</td>
<td>Panuveitis</td>
<td>+2 Anterior chamber cells&lt;br&gt;Posterior synechiae&lt;br&gt;+2 Vitritis&lt;br&gt;Retinitis&lt;br&gt;Diffuse macular edema</td>
<td>None&lt;br&gt;Subtle retinal pigment epithelial changes (12 weeks)</td>
<td>1.000&lt;br&gt;1.000</td>
<td>0.900&lt;br&gt;0.500</td>
</tr>
<tr>
<td>3</td>
<td>OD</td>
<td>Idiopathic uveitis</td>
<td>Loss of vision Floaters</td>
<td>Posterior</td>
<td>Sub-foveal lesion</td>
<td>Foveal scar (12 weeks)</td>
<td>0.500&lt;br&gt;Foveal scar, cataract</td>
<td>0.500</td>
</tr>
<tr>
<td>4</td>
<td>OD</td>
<td>Idiopathic uveitis</td>
<td>Floaters</td>
<td>Posterior</td>
<td>+1 Vitritis&lt;br&gt;Vasculitis&lt;br&gt;Choroiditis</td>
<td>None&lt;br&gt;(8 weeks after 3rd antibiotic; 6 months after 1st antibiotic)</td>
<td>1.000&lt;br&gt;1.000</td>
<td>0.800</td>
</tr>
<tr>
<td>5</td>
<td>OD</td>
<td>Idiopathic retinal central vein thrombosis</td>
<td>Loss of vision Floaters</td>
<td>Posterior</td>
<td>+2 Vitritis&lt;br&gt;Vasculitis (phlebitis)&lt;br&gt;Retinal venous tortuosity&lt;br&gt;Retinal hemorrhages&lt;br&gt;Macular edema</td>
<td>None&lt;br&gt;(8 weeks after 3rd antibiotic; 6 months after 1st antibiotic)</td>
<td>1.000&lt;br&gt;1.000</td>
<td>0.300</td>
</tr>
<tr>
<td>6</td>
<td>OD</td>
<td>Idiopathic intermediate uveitis</td>
<td>Redness Pain Blurred vision</td>
<td>Panuveitis</td>
<td>Anterior chamber cells&lt;br&gt;Posterior synechiae&lt;br&gt;+1 Vitritis&lt;br&gt;Vitreous exudates&lt;br&gt;Retinal hemorrhages</td>
<td>None&lt;br&gt;(8 weeks after 2nd antibiotic; 4 months after 1st antibiotic)</td>
<td>1.000&lt;br&gt;1.000</td>
<td>0.800</td>
</tr>
<tr>
<td>7</td>
<td>OD</td>
<td>Panuveitis VKH</td>
<td>Loss of vision</td>
<td>Posterior</td>
<td>+2 Vitritis&lt;br&gt;Vasculitis&lt;br&gt;Choroiditis&lt;br&gt;Macular edema</td>
<td>Focal choroidal scars&lt;br&gt;Vascular attenuation&lt;br&gt;Chronic macular edema (4 weeks after 2nd antibiotic; 3 months after 1st antibiotic)</td>
<td>0.200&lt;br&gt;0.100</td>
<td>0.100&lt;br&gt;Chronic macular edema</td>
</tr>
<tr>
<td>OS</td>
<td>Panuveitis VKH</td>
<td>Loss of vision</td>
<td>Posterior</td>
<td>+2 Vitritis&lt;br&gt;Vasculitis&lt;br&gt;Disseminated choroiditis&lt;br&gt;Focal nodules&lt;br&gt;Macular edema</td>
<td>Focal choroidal scars&lt;br&gt;Vascular attenuation&lt;br&gt;Chronic macular edema (4 weeks after 2nd antibiotic; 4 months after 1st antibiotic)</td>
<td>0.300&lt;br&gt;0.300</td>
<td>0.160&lt;br&gt;Cataract</td>
<td>0.160</td>
</tr>
</tbody>
</table>

**Notes:** *Uveitis classification according to anatomic location.*<sup>23</sup> **Grading of anterior chamber cells and vitreous cells (vitriris) according to SUN working group.*<sup>24</sup>

**Abbreviations:** OD, right eye; OS, left eye; OU, both eyes; BCVA, best corrected visual acuity; FU, follow-up; VKH, Vogt-Koyanagi-Harada.
R. conorii, R. slovaca, and R. helvetica are the species reported in these areas. The last two have been associated with atypical MSF, without exanthem.

All our patients were originally from the regions of Extremadura and Andalucia, where MSF is endemic. Most of our patients could not remember a history of insect bites, but could not deny it either. In general, 73% of patients deny having a history of tick bite, which agrees with our series, where only two patients reported insect bites.

Although most of our patients had no typical systemic manifestations of MSF, they did have positive serology for R. conorii or Rickettsia spp. infection. Cases 2, 6, and 7 had a previous history of arthralgias, which can be caused by these or other entities. In Case 2, the child’s uveitis (Figure 3A to 3C) was diagnosed 3 months before a reported fever episode and appearance of a hyperemic papule. He had IgM titers of 1/40, which met European criteria for Rickettsia spp. infection. All individuals in this series except Case 2 had IgG and/or IgM levels that met European criteria for R. conorii infection.

Ocular involvement in MSF commonly occurs as vasculitis (55.9%), choroiditis (16.7%), serous retinal detachment (5%), cystoid macular edema (1.7%), and others. Keratitis, oculoglandular syndrome, endogenous panuveitis, vitreous hemorrhage, panuveitis with occlusive vasculitis, and chorioretinitis have also been reported. Our patients had choroiditis, vasculitis, central retinal vein occlusion,
eventually decreased to 1/640.33 The patient denied contact with animals or tick bite, like some of our patients. It is important to note the lack of antibodies to other Rickettsia at the time Bonnet’s article was published, thus it is possible that any of the spotted fever group Rickettsia could have caused those findings.33

In Case 4, birdshot choroidopathy was diagnosed after clinical diagnosis and being positive with HLA-A29. However the patient did not improve after immunosuppressive therapy and had concomitant high IgG anti-R. conorii titers. Ocular inflammation improved and IgM and IgG anti-R. conorii titers decreased after three antibiotic courses, thus supporting our diagnosis of R. conorii infection. Cross reactivity with the HLA-A29 antigen has previously been considered in similar cases of birdshot choroidopathy with B. burgdorferi and Coxiella burnetti, formerly classified as a member of the order Rickettsiales,23 but not with R. conorii.35,36 The hypothesis of molecular mimicry has been proposed to explain the link between Gram negative bacteria and HLA-B27 in the pathogenesis of ankylosing spondylitis.37 This could explain the association between tickborne bacteria, like R. conorii, C. burnetti, and B. burgdorferi, and HLA-A29 in the pathogenesis of birdshot choroidopathy. However this patient came from an area where rickettsiosis is endemic. Further, she showed high titers of anti-R. conorii IgM and IgG, which would argue against possible cross reactivity.

Since pure ocular rickettsiosis has already been reported for R. conorii, we believe all cases, except Case 2, represent R. conorii infection limited to the eye. They all had ocular inflammation and positive anti-R. conorii IgG and/or IgM titers that are compatible with European criteria for R. conorii infection and which decreased after antibiotic treatment.

Based on the clinical and serologic progress of these seven rare cases, they epitomize uveitis by spotted fever group Rickettsias as the main manifestation of the disease. The fact that most patients came from known endemic areas led us to conclude that R. conorii should be always considered as a cause of uveitis in Spain and most likely in other Mediterranean countries. Although R. conorii was not reported as a common cause in a recent study on uveitis patterns in various geographic regions, we believe this bacterium and related species should be included in the work-up of patients with uveitis who live in endemic areas.38

Acknowledgments
The authors express their appreciation to Dr JM Guerra Campos and Dr Bolivia Vera for referring patients to IOBA.
Disclosure
Hernan Martinez-Osorio and Graciana Fuentes-Paez were supported by a grant from the Carolina Foundation, Ministry of Foreign Affairs, Spain. Archimedes LD Agahan was supported by a scholarship grant from the Agencia Española de Cooperacion Internacional (AECI), Ministry of Foreign Affairs, Spain.

References

Clinical Ophthalmology
Publish your work in this journal
Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.